ArticleMarine drugs2020
Improvement of Psoriasis by Alteration of the Gut Environment by Oral Administration of Fucoidan from
Article in Marine drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- Trial
- Multidisciplinary Management of Psoriasis: Integrating Diet, Exercise, Psychological Support, and Sleep Interventions.Clinical, cosmetic and investigational dermatology · 2025Review
- Fucoidan as a therapeutic agent for ulcerative colitis: mechanisms of action and modulation of the gut microbiota.Frontiers in cellular and infection microbiology · 2025Review
- Revealing the Potential ofMarine drugs · 2024Article
- Dietary Fiber Inulin Improves Murine Imiquimod-Induced Psoriasis-like Dermatitis.International journal of molecular sciences · 2023Article
- Beneficial effects of seaweed-derived components on metabolic syndrome via gut microbiota modulation.Frontiers in nutrition · 2023Review
- Gut Microbiota in Psoriasis.Nutrients · 2022Review
- The Prebiotic Effect of Australian Seaweeds on Commensal Bacteria and Short Chain Fatty Acid Production in a Simulated Gut Model.Nutrients · 2022Article
- Anti-Inflammatory Potential of Fucoidan for Atherosclerosis: In Silico and In Vitro Studies in THP-1 Cells.Molecules (Basel, Switzerland) · 2022Article
- Nutritional Therapy in Persons Suffering from Psoriasis.Nutrients · 2021Review
- The Defect in Regulatory T Cells in Psoriasis and Therapeutic Approaches.Journal of clinical medicine · 2021Review
- Fucoidans and Bowel Health.Marine drugs · 2021Review
- Seaweed Components as Potential Modulators of the Gut Microbiota.Marine drugs · 2021Review
- Article
- Daily Lifestyle and Inflammatory Skin Diseases.International journal of molecular sciences · 2021Review
- Nutrition and Psoriasis.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic autoimmune inflammatory disease for which there is no cure; it results in skin lesions and has a strong negative impact on patients' quality of life. Fucoidan from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.